These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32185027)

  • 1. Severe muscle pain and stiffness due to dexmethylphenidate.
    Kon JJ; Kon AA
    Clin Case Rep; 2020 Mar; 8(3):420-422. PubMed ID: 32185027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexmethylphenidate for attention deficit hyperactivity disorder.
    Coury D
    Expert Opin Pharmacother; 2009 Nov; 10(16):2679-85. PubMed ID: 19874250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.
    McGough JJ; Pataki CS; Suddath R
    Expert Rev Neurother; 2005 Jul; 5(4):437-41. PubMed ID: 16026226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.
    Brams M; Muniz R; Childress A; Giblin J; Mao A; Turnbow J; Borrello M; McCague K; Lopez FA; Silva R
    CNS Drugs; 2008; 22(8):693-704. PubMed ID: 18601306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.
    Moen MD; Keam SJ
    CNS Drugs; 2009 Dec; 23(12):1057-83. PubMed ID: 19958043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.
    Pheils J; Ehret MJ
    Am J Health Syst Pharm; 2021 May; 78(10):840-849. PubMed ID: 33954419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder.
    Robinson DM; Keating GM
    Drugs; 2006; 66(5):661-8; discussion 669-70. PubMed ID: 16620143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating serdexmethylphenidate and dexmethylphenidate capsules as a once-daily treatment option for ADHD.
    Barnhardt EA; Narayanan AR; Coury DL
    Expert Opin Pharmacother; 2023; 24(11):1215-1219. PubMed ID: 37226489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and efficacy of methylphenidate and dexmethylphenidate in adults with attention deficit/hyperactivity disorder.
    Sopko MA; Caberwal H; Chavez B
    J Cent Nerv Syst Dis; 2010; 2():15-30. PubMed ID: 23861628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study.
    Childress AC; Marraffino A; Cutler AJ; Oh C; Brams MN
    J Child Adolesc Psychopharmacol; 2023 Mar; 33(2):51-58. PubMed ID: 36809150
    [No Abstract]   [Full Text] [Related]  

  • 11. Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.
    Sugrue D; Bogner R; Ehret MJ
    Am J Health Syst Pharm; 2014 Jul; 71(14):1163-70. PubMed ID: 24973373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder.
    Perugi G; Vannucchi G
    Expert Opin Pharmacother; 2015; 16(14):2193-204. PubMed ID: 26364896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Investigational Drugs for the Treatment of Attention-Deficit/Hyperactivity Disorder.
    Childress A; Tran C
    Expert Opin Investig Drugs; 2016; 25(4):463-74. PubMed ID: 26814173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in maintenance of response upon discontinuation across medication treatments in attention-deficit/hyperactivity disorder.
    Buitelaar J; Asherson P; Soutullo C; Colla M; Adams DH; Tanaka Y; Haynes VS; Escobar R; Upadhyaya H
    Eur Neuropsychopharmacol; 2015 Oct; 25(10):1611-21. PubMed ID: 26169574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
    May DE; Kratochvil CJ
    Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts.
    Stein MA; Waldman ID; Charney E; Aryal S; Sable C; Gruber R; Newcorn JH
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):581-8. PubMed ID: 22136094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
    CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-Term Vision-Related Ocular Side Effects of Treatment with Dexmethylphenidate for Attention-Deficit/Hyperactivity Disorder.
    Fainberg G; Leitner Y; Zur D; Klein A; Mezad-Koursh D
    J Child Adolesc Psychopharmacol; 2022 Dec; 32(10):533-538. PubMed ID: 36548361
    [No Abstract]   [Full Text] [Related]  

  • 19. Dexmethylphenidate--Novartis/Celgene. Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride.
    Drugs R D; 2002; 3(4):279-82. PubMed ID: 12455205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations.
    Patrick KS; Radke JL; Raymond JR; Koller L; Nguyen LV; Rodriguez W; Straughn AB
    Pharmacotherapy; 2019 Jun; 39(6):677-688. PubMed ID: 30351459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.